Healthcare leaders set to thrive post-COVID

Article Excerpt

We think the healthcare industry will enjoy great success over the next decade. But due to the nature of the business, results will vary widely and unpredictably from one company to another. A volatile market like the one we expect for healthcare stocks will include winners and losers. Here are two that we expect to be among the big winners. REGENERON PHARMACEUTICALS INC., $636.34, is a buy. Your shares (Nasdaq symbol REGN; TSINetwork Rating: Average) (www.regeneron.com; Shares outstanding: 107.2 million; Market cap: $70.7 billion; No dividends paid) let you tap this leading inventor, developer and producer of a range of medicines for the treatment of serious and debilitating conditions. They include eye disease, cancer and rare inflammatory conditions. Regeneron has eight FDA-approved medicines, all of which it developed in its own laboratories. The best-selling of the bunch is Eylea to treat macular degeneration. In the quarter ended June 30, 2022, Regeneron’s revenue fell 44.4%, to $2.86 billion from $5.14 billion a year earlier. Last year’s revenue included…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.